AIM: To define the sub site distribution of upper gastrointestinal cancers in three provinces of Iran. METHODS: The study was carried out in three provinces in Iran: Ardabil, Golestan, and Tehran. In Arbabil and Golestan, the data was collected from the sole referral center for gastrointestinal cancers and the local cancer registry. For Tehran province, data from two major private hospitals were used. All gastric and esophageal cancer patients diagnosed during the period from September 2000 and April 2002 were included in the study. RESULTS: A total of 761 patients with upper gastrointestinal cancers were identified, 314 from Ardabil, 261 from Golestan, and 186 from Tehran. In Tehran, the relative rate of cancer increased from the upper esophagus to the distal stomach. In Golestan, the reverse pattern was observed. In Ardabil, the mid portion (distal esophagus and proximal stomach) was involved most frequently. CONCLUSION: There were considerable variations in the sub site of upper gastrointestinal cancers in the three provinces studied. We cannot provide any explanation for this variation. Further research aimed at explaining the discrepancies in sub site distribution of upper gastrointestinal cancers may help identify important risk factors.
AIM: To define the sub site distribution of upper gastrointestinal cancers in three provinces of Iran. METHODS: The study was carried out in three provinces in Iran: Ardabil, Golestan, and Tehran. In Arbabil and Golestan, the data was collected from the sole referral center for gastrointestinal cancers and the local cancer registry. For Tehran province, data from two major private hospitals were used. All gastric and esophageal cancerpatients diagnosed during the period from September 2000 and April 2002 were included in the study. RESULTS: A total of 761 patients with upper gastrointestinal cancers were identified, 314 from Ardabil, 261 from Golestan, and 186 from Tehran. In Tehran, the relative rate of cancer increased from the upper esophagus to the distal stomach. In Golestan, the reverse pattern was observed. In Ardabil, the mid portion (distal esophagus and proximal stomach) was involved most frequently. CONCLUSION: There were considerable variations in the sub site of upper gastrointestinal cancers in the three provinces studied. We cannot provide any explanation for this variation. Further research aimed at explaining the discrepancies in sub site distribution of upper gastrointestinal cancers may help identify important risk factors.
Authors: Mehdi Nouraie; Amir R Radmard; Hanieh Zaer-Rezaii; Hadi Razjouyan; Siavosh Nasseri-Moghaddam; Reza Malekzadeh Journal: Am J Gastroenterol Date: 2007-04-16 Impact factor: 10.864
Authors: S Massarrat; M Saberi-Firoozi; A Soleimani; G W Himmelmann; M Hitzges; H Keshavarz Journal: Eur J Gastroenterol Hepatol Date: 1995-05 Impact factor: 2.566
Authors: A Pourshams; M Saadatian-Elahi; M Nouraie; A F Malekshah; N Rakhshani; R Salahi; A Yoonessi; S Semnani; F Islami; M Sotoudeh; S Fahimi; A R Sadjadi; D Nasrollahzadeh; K Aghcheli; F Kamangar; C C Abnet; F Saidi; V Sewram; P T Strickland; S M Dawsey; P Brennan; P Boffetta; R Malekzadeh Journal: Br J Cancer Date: 2005-01-17 Impact factor: 7.640
Authors: F Islami; F Kamangar; K Aghcheli; S Fahimi; S Semnani; N Taghavi; H A Marjani; S Merat; S Nasseri-Moghaddam; A Pourshams; M Nouraie; M Khatibian; B Abedi; M H Brazandeh; R Ghaziani; M Sotoudeh; S M Dawsey; C C Abnet; P R Taylor; R Malekzadeh Journal: Br J Cancer Date: 2004-04-05 Impact factor: 7.640
Authors: Sadaf G Sepanlou; Arash Etemadi; Farin Kamangar; Alireza Sepehr; Akram Pourshams; Hossein Poustchi; Farhad Islami; Alireza Sadjadi; Dariush Nasrollahzadeh; Shahryar Semnani; Farrokh Saidi; Christian C Abnet; Bruce Ponder; Paul D Pharoah; Nicholas E Day; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Reza Malekzadeh Journal: Arch Iran Med Date: 2013-01 Impact factor: 1.354
Authors: Y Yahyapour; M Shamsi-Shahrabadi; M Mahmoudi; A Motevallian; S Siadati; S Shefaii; J Shokri Shirvani; H R Mollaie; Seyed Hamid Reza Monavari; Hossein Keyvani Journal: Pathol Oncol Res Date: 2012-12-19 Impact factor: 3.201